Viz.ai is a pioneering healthcare technology company specializing in artificial intelligence (AI)-powered disease detection and intelligent care coordination. Founded in 2016 by Dr. Chris Mansi, a former neurosurgeon, and David Golan, a machine learning postdoctoral researcher, the company is headquartered in San Francisco, California. Viz.ai's mission is to enhance patient outcomes by leveraging AI to expedite diagnosis and treatment processes across various medical conditions.
Company Overview
Viz.ai's flagship product, the Viz.ai One platform, utilizes AI algorithms to analyze medical imaging and other patient data, enabling rapid identification of diseases such as strokes, pulmonary embolisms, and aortic dissections. The platform integrates seamlessly with electronic health records (EHRs) and radiology systems, facilitating real-time communication among healthcare providers and streamlining patient care pathways. As of January 2024, Viz.ai's solutions are deployed in over 1,500 hospitals across the United States, including the majority of the 50 largest healthcare systems, serving more than 45,000 healthcare providers.
Financial Performance
In April 2022, Viz.ai secured $100 million in Series D funding, led by Tiger Global and Insight Partners, elevating the company's valuation to $1.2 billion. By 2023, the company achieved an estimated revenue of $40 million, marking a 74% year-over-year growth. Projections for 2024 anticipate revenue reaching approximately $65 million.
Product Portfolio
The Viz.ai One platform encompasses a suite of FDA-approved algorithms designed for the detection and triage of various medical conditions, including:
- Stroke Detection: The platform's AI algorithms can identify large vessel occlusion (LVO) strokes from CT scans, significantly reducing the time to treatment.
- Cardiology Solutions: In 2023, Viz.ai introduced Viz HCM, the first regulatory-approved hypertrophic cardiomyopathy AI detection algorithm and workflow tool.
- Pulmonary Embolism Detection: The platform includes AI-driven solutions for detecting pulmonary embolisms, enhancing the speed and accuracy of diagnosis.
These tools are designed to expedite diagnosis, improve care coordination, and ultimately enhance patient outcomes.
Market Position and Competitors
Viz.ai operates in the competitive landscape of AI-driven healthcare solutions, facing competition from companies such as Aidoc, Qure.ai, and RapidAI, which also offer AI-based medical imaging analysis. Additionally, established medical technology firms like GE Healthcare, Siemens Healthineers, and Philips are investing in AI capabilities to enhance their existing offerings. Viz.ai differentiates itself through its comprehensive care coordination platform, which integrates AI diagnostics with streamlined communication tools, enabling faster triage and treatment decisions.
Strategic Partnerships
Viz.ai has established collaborations with several leading life science companies to enhance its platform and expand its reach. By January 2024, the company had formed partnerships with seven of the top 30 global life science companies, aiming to streamline patient journeys and accelerate access to therapies.
Awards and Recognition
The company's innovative approach has garnered significant recognition:
- Forbes AI 50: Viz.ai has been named to Forbes' AI 50 list multiple times, including in 2023, highlighting its status as one of the most promising private AI companies globally.
- Fast Company's Most Innovative Companies: In 2024, Viz.ai was recognized by Fast Company as one of the world's most innovative companies, underscoring its impact on healthcare through AI.
Future Outlook
Looking ahead, Viz.ai aims to continue expanding its AI-powered solutions across various medical specialties, enhancing its platform's capabilities, and forging new partnerships to further its mission of improving patient outcomes through intelligent care coordination.
